NCT06424665View on ClinicalTrials.gov

A Study of FZ-AD005 in Patients With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

162

Participants

Timeline

Start Date

July 3, 2024

Primary Completion Date

December 1, 2025

Study Completion Date

June 1, 2026

Conditions
Advanced Solid Tumor, SCLC(Small Cell Lung Cancer) or LCNEC (Large Cell Neuroendocrine Carcinoma)
Interventions
DRUG

FZ-AD005

Every 21 days for 1 cycle. Subjects will receive an intravenous infusion of FZ-AD005 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.

Trial Locations (3)

200120

RECRUITING

Shanghai East Hospital, Shanghai

310022

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

410013

RECRUITING

Hunan Cancer Hospital, Changsha

All Listed Sponsors
lead

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

INDUSTRY